Plasma Levels of Interleukin 1β and Interleukin 6 in Mental Disorders

  • K. Schott
  • A. Batra
  • A. Uhl
  • M. Bartels
  • G. Buchkremer
Conference paper
Part of the Key Topics in Brain Research book series (KEYTOPICS)


It was concluded from alterations of interleukins in CSF and plasma that patients with schizophrenia and major depression exhibit an acute stimulation of the immune system [1, 2, 3, 4]. In this context an underlying autoimmune process was assumed in the pathology of schizophrenia and major depression. Especially schizophrenia with its relapsing and chronic forms reminds of the course of autoimmune diseases like chronic rheumatic illness [5, 6].


Major Depression Schizophrenic Patient Paranoid Schizophrenia BioI Psychiatry Phrenic Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Ganguli R, McAllister CG, Rabin BS, Solomon W, Brar JS, Rehn I (1991) Alterations in interleukins and in lymphocyte subsets in a subgroup of schizophrenia. Biol Psychiatry 29:109 AGoogle Scholar
  2. [2]
    Shintani F, Kanba S, Marno N, Nakaki T, Nibuya M, Suzuki E, Kinoshita N, Yagi G (1991) Serum interleukin 6 in schizophrenic patients. Life Sci 49: 661 – 664PubMedCrossRefGoogle Scholar
  3. [3]
    Licinio J, Seibyl JP, Altemus M, Charney DS, Krystal JH (1993) Elevated CSF levels of interleukin-2 in neuroleptic free schizophrenic patients. Am J Psychiatry ISO: 1408 – 1410Google Scholar
  4. [4]
    Maes M, Stevens WJ, Declerck LS, Bridts CH, Peeters D, Schotte G, Cosyns P (1993) Significantly increased expression of T-cell activation markers (Interleu-kin-2 and HAL-DR) in depression. Further evidence for an inflammatory process during that illness. Progr Neuropsychopharmacol Biol Psychiatry H: 241 – 255Google Scholar
  5. [5]
    Knight J, Knight A, Ungvari G (1992) Can autoimmune mechanisms account for the genetic predisposition to schizophrenia? Br J Psychiatry 160: 533 – 540PubMedCrossRefGoogle Scholar
  6. [6]
    DeLisi LE, Weber RJ, Pert CB (1985) Are there antibodies against brain in sera from schizophrenic patients? Review and prospectus. Biol Psychiatry 20: 94 – 119CrossRefGoogle Scholar
  7. [7]
    Ganguli R, Rabin BS, Kelly RFL Lyte M, Ragu U (1987) Clinical and laboratory evidence of autoimmunity in acute schizophrenia. Ann NY Acad Sci 496: 676 – 685PubMedCrossRefGoogle Scholar
  8. [8]
    Heath RG, McCarron KL, O’Neil CE (1989) Antiseptal brain antibody in IgG of schizophrenic patients. Biol Psychiatry 25: 725 – 733PubMedCrossRefGoogle Scholar
  9. [9]
    Roy BF, Rose JW, Sunderland T, Morihsa JM, Murphy DL (1988) Antisomatostatin IgG in major depressive disorder. Arch Gen Psychiatry 45: 924 – 928PubMedGoogle Scholar
  10. [10]
    Schott K, Batra A, Klein R, Battels M, Koch W, Berg PA (1992) Antibodies against serotonin and gangliosides in schizophrenia and major depressive disorder. Eur Psychiatry 7: 209 – 212Google Scholar
  11. [11]
    Brauchitsch H (1972) Antinuclear factor in psychiatric disorders. Am J Psychiatry 128: 1552 – 1554Google Scholar
  12. [12]
    Sirota P, Firer MA, Schilcl K, Tanay A, Elizur A, Meytes D, Slor H (1993) Auto-antibodies to DNA in multi case families with schizophrenia. Biol Psychiatry 33: 450 – 455PubMedCrossRefGoogle Scholar
  13. [13]
    Ehrnst A, Wiesel FA, Bjerkenstedt LB, Tribukait B, Jonsson J (1982) Failure to detect immunological stigmata in schizophrenia. Neuropsychobiol 8: 169 – 171CrossRefGoogle Scholar
  14. [14]
    Knight JG, Knight A, Menkes DB, Mullen PE (1990) Autoantibodies against brain septal region antigens specific to unmedicated schizophrenia? Biol Psychiatry 28: 467 – 474PubMedCrossRefGoogle Scholar
  15. [15]
    Fontana A, Storck U, Angst J, Dubs R, Abegg A, Grob PJ (1980) An immunological basis of schizophrenia and affective disorders? Neuropsychobiol 6: 284 – 289CrossRefGoogle Scholar
  16. [16]
    Whalley LJ, Roberts DF, Wentzel J, Watson KL (1981) Antinuclear antibodies and histocompatibility antigens in patients on long-term lithium therapy. J Affect Disord 3: 123 – 130PubMedCrossRefGoogle Scholar
  17. [17]
    Maes M, Bosmans E, Meltzer HY, Scharpe S, Suy E (1993) Interleukin-1β: a putative mediator of HPA axis hyperactivity in major depression. Am J Psychiatry 150: 1189 – 1193PubMedGoogle Scholar
  18. [18]
    Rapaport MH, Torrey EF, McAllister CG, Nelson DL, Pickar D, Paul SM (1993) Increased serum soluble interleukin 2-receptors in schizophrenic monozygotic twins. Eur Arch Psychiatry Clin Neurosci 243: 7 – 10PubMedCrossRefGoogle Scholar
  19. [19]
    Yang ZLO, Chengappa KNR, Shurin G, Brar JS, Rabin BS, Gubbi AN, Ganguli R (1994) An association between anti-hipocampal antibody concentration and lymphocyte production of Il-2 in patients with schizophrenia. Psychol Med 24: 449 – 455PubMedCrossRefGoogle Scholar
  20. [20]
    Maes M, Meltzer HY, Buckley P, Bosmans E (1995) Plasma soluble interleukin-2 and transferin receptor in schizophrenia and major depression. Eur Arch Psychiatry Clin Neurosci 244: 325 – 329PubMedCrossRefGoogle Scholar
  21. [21]
    Katila H, Hurme M, Wahlbeck K, Appelberg B, Rimond R (1994) Plasma and cerebrospinal fluid interleukin-1βand interleukin-6 in hospitalized schizophrenic patients. Neuropsychobiol 30: 20 – 30CrossRefGoogle Scholar
  22. [22]
    Spitzer RL, Endicott J, Robins E (1978) Research diagnostic criteria. Arch Gen Psychiatry 35: 773 – 782PubMedGoogle Scholar
  23. [23]
    Xu HM, Wie J, Hemmings GB (1994) Changes of plasma concentrations of interleukin-1α and interleukin-6 with neuroleptic treatment for schizophrenia. Br J Psychiatry 164:251 –253PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1997

Authors and Affiliations

  • K. Schott
    • 1
  • A. Batra
    • 1
  • A. Uhl
    • 1
  • M. Bartels
    • 1
  • G. Buchkremer
    • 1
  1. 1.Psychiatrische UniversitätsklinikTübingenFederal Republic of Germany

Personalised recommendations